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Abstract
Background: Undiagnosed airflow limitation is common in the general population and is associated with impaired
health and functional status. Smoking is the most important risk factor for this condition. Although primary care
practitioners see most adult smokers, few currently have spirometers or regularly order spirometry tests in these
patients. Brief medical advice has shown to be effective in modifying smoking habits in a large number of smokers
but only a small proportion remain abstinent after one year. The aim of this study is to evaluate the effectiveness
of regular reporting of spirometric results combined with a smoking cessation advice by a primary care physician
on smoking quit rate in adult smokers.
Methods/design: Intervention study with a randomized two arms in 5 primary care centres. A total of 485
smokers over the age of 18 years consulting their primary care physician will be recruited.
On the selection visit all participants will undergo a spirometry, peak expiratory flow rate, test of smoking
dependence, test of motivation for giving up smoking and a questionnaire on socio-demographic data. Thereafter
an appointment will be made to give the participants brief structured advice to give up smoking combined with a
detailed discussion on the results of the spirometry. After this, the patients will be randomised and given
appointment for follow up visits at 3, 6, 12 and 24 months. Both arms will receive brief structured advice and a
detailed discussion of the spirometry results at visit 0. The control group will only be given brief structured advice
about giving up smoking on the follow up. Cessation of smoking will be tested with the carbon monoxide test.
Discussion: Early identification of functional pulmonary abnormalities in asymptomatic patients or in those with
little respiratory symptomatology may provide “ideal educational opportunities”. These opportunities may increase
the success of efforts to give up smoking and may improve the opportunities of other preventive actions to
minimise patient risk. Comparing adult smokers in the intervention group with those in the control group, a
minimum improvement expected with respect to the rates of smoking cessation would represent a large number
of avoided morbimortality.
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Background
Chronic obstructive pulmonary disease (COPD) involves
a heterogeneous group of processes characterised by lit-
tle reversible air flow obstruction of chronic and pro-
gressively disabling evolution which causes a high
morbimortality around the world. According to the
World Health Organisation (WHO) 210 million people
around the world have COPD [1] and despite being a
potentially avoidable disease, has foreseen that in 2030
COPD will be the cause of 7.8% of all deaths and 27%
of the deaths related to smoking only by cancer and car-
diovascular diseases [2].
In addition to increasing the mortality, its prevalence
is also slowly rising so epidemiological predictions fore-
see a growing trend in the next decades [3]. These and
other reasons have converted this health care problem
into a priority in the most important international insti-
tutions [4]. In our setting the high prevalence of COPD
in parallel with the smoking habit have been consis-
tently emphasised [5]. The IBERPOC study has evalu-
ated COPD among 9% of the Spanish population
between 40 to 69 years of age, a percentage that
increases up to 23% in subjects over the age of 60 years
[6]. At the time of the study, 48% of the population
reported some respiratory symptom (13.5% cough,
10.7% chronic expectoration and 10.4% dyspnea) always
higher frequency in men.
The diagnosis of COPD is clear and its treatment is
feasible. However, a high number of patients remain
undiagnosed and therefore not treated. Interestingly, the
letters of COPD coincide with “Confusion Over Patient
Diagnosis” [7]. In Spain, data of the IBERPOC study
c o n f i r mt h a tu n d e r d i a g n o s i si sf r e q u e n t( 7 8 . 1 % )a n di s
accompanied by undertreatment (80.7%) [8]. The rea-
sons include not only certain nihilistic attitudes towards
treatment but also an initial symptomatology makes
diagnosis difficult [9]. The preliminary results of the
EPI-SCAN study performed 10 years after the IBERPOC
have confirmed the high rate of underdiagnosis of
COPD in Spain with a prevalence of 10.2% in the popu-
lation from 40 to 80 years of age. Underdiagnosis 10
years later was slightly reduced from 78% in the IBER-
POC study to 73% in EPI-SCAN. Moreover, undertreat-
ment was reduced from 81% to 54% [10].
From a more economic point of view, the morbimor-
tality associated with COPD has an enormous social and
individual impact. It has been estimated that COPD
consumes 2% of the Spanish health care budget repre-
senting approximately 0.25% of the Gross National Pro-
duct. A recent study has shown an average annual cost
per patient of $ 1,760 [11]. Family practitioners are in
the best position to change this scenario.
Aetiopathogenics of COPD are multifactorial. A his-
tory of smoking is invariably found in most cases,
although 15% to 20% of smokers develop the disease
[12]. Thus, the presence of smoking habit and suggestive
symptomatology make functional respiratory evaluation
compulsary for early detection of respiratory disease
obligatory [13]. Forced spirometry is a simple reproduci-
ble test and an objective method to quantify airflow
obstruction in the early phases. Several studies have
reported that forced spirometry in subjects at risk is a
highly effective strategy for diagnosis of COPD. Investi-
gators from the University of Maastricht performed this
approach in the primary care setting and demonstrated
its efficacy [14]. According to this study, the probability
of detecting spirometric alterations in smokers over 40
years of age with chronic cough is 2.5-fold greater than
in non smokers. Likewise, a multicentre study carried
out in 12 primary care centres showed a prevalence of
COPD of 30.6% among smokers of 10 packs/year over
the age of 40 [15].
The risks derived from smoking are well known in the
biomedical community and political class, and increas-
ingly more, by the society in general. The international
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) consensus insists that smoking is the most
important risk factor for the development of COPD and
thus, antismoking advice should be the first therapeutic
recommendation [16]. However, this obvious objective is
not at all easy to achieve. At present, 29% of the Eur-
opean Union population is considered to be a regular
smoker. According to the last Health Care Plan of Cata-
lonia, in 1998 the smoking prevalence in the population
from 15 to 64 years of age was 37.5% (30.7% in women
and 44.4% in men)[17]. The last National Health Survey
of 2006 carried out by the Spanish Ministry of Health
showed the smoking prevalence was 26.4% over 16 years
of age (31.6% in men and 21.5% in women ) with 42%
smoking ≥ 20 cigarettes / day (50.2% men and 31.6%
women) [18].
Cessation of smoking is the simplest and most prof-
itable preventive method to avoid the development of
COPD. It is also the most effective therapeutic inter-
vention in already diagnosed patients and is the only
effective method to increase survival [19]. Giving up
smoking has an immediate effect on both pulmonary
function and the risk of hospitalisation and total mor-
tality [20]. Many studies have shown that smoking ces-
sation produces an improvement in respiratory
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with COPD [21].
The IBERPOC study reported that almost 70% of the
subjects with mild COPD were smokers and many were
in the precontemplative phase [22]. Another added pro-
blem is relapse of smoking which is of 70% during the
first year in the general smoker population. These values
are greater in the COPD group [23]. This fight has
b e c o m eap r i o r i t yi nt h ep u b l ic health care setting for
most governments of developed countries. As early
as1986, the WHO agreed that smoking, in any of its
forms, was incompatible with its strategic objectives.
Many strategies have been considered to fight smok-
ing and these may essentially be classified into 3 large
groups: market regulation, taxation on the price of
tobacco, and health protection [24]. The promotion of
healthy lifestyles is the most effective and efficient strat-
egy within the public health setting. According to the
evidence available, both isolated medical advice as well
as therapy with pharmacologic measures, have shown to
be effective in the approach towards smoking. The
health care costs of treatment, such as a minimum med-
ical intervention or using nicotine substitutes or other
drugs, would be lower than resources devoted to other
prevalent diseases such as arterial hypertension or
hypercholesterolemia. With regard to isolated medical
advice, this has shown to be effective in modifying the
smoking habit in a large number of smokers, although
only a small proportion of these patients remained absti-
nent after one year [25]. Although these values may vary
according to the different studies, the differences found
are small and range from a modest 2% described in the
review by Law and Tang [26] to 11% achieved by Torre-
cilla et al [27] in an autochthonous study. According to
recently published data, reprinting of air flow obstruc-
tion by spirometry together with antismoking advice
would increase the percentage of success by 16.5%, com-
pared to using pharmacologic agents [28]. The results
obtained may seem to be modest but from a popula-
tional point of view any strategy to reduce the consump-
tion of tobacco, regardless of being small in relative
terms, is very beneficial in absolute numbers with
respect to both avoidable diseases and cost saving in the
health system.
The different strategies used to reduce smoking con-
sumption have been evaluated by the Cochrane Library.
Biomedical risk as an aid in smoking cessation was
assessed and it was concluded that there are few tests
on the effects of most of the biomedical tests available
to evaluate risks [29]. Spirometry combined with inter-
pretation of the results in relation to pulmonary age
presented a significant effect of 13.6% on the rate of
smoking cessation in the intervention group at 12
months and of 6.4% in the control group [30].
Indeed, although adequate tools for aiding patients to
give up smoking are currently available, the percentages
of success may be insufficient if the objective is to
achieve a reduction in the prevalence of smoking. It is
essential to investigate broad new populational
approaches which reduce the magnitude of the problem,
particularly when COPD is already present. If it is taken
into account that spirometry is a simple and accessible
test and that up to 70% of the smokers consult primary
care physicians at least once a year, it is logical to
assume that the opportunities of the family practitioners
to diagnose the disease and offer antismoking advice are
high and even more so when the work setting is the
ideal place to do this.
Methods/Design
Study Objectives
Main objective
To evaluate the effectiveness of regular reporting of
spirometric results combined with a smoking cessation
advice by a primary care physician on smoking quit rate
in adult smokers.
Secondary objective
To evaluate the validity of the peak expiratory flow rate
to detect COPD in adult smokers and determine the
prevalence of COPD and the severity of the limitation of
airflow in adult smokers attended in primary care.
Study design and setting
Interventional study with two randomized arms in 5 pri-
mary care centers of two health areas in the Maresme
region (Catalonia, Spain). A total of 392 smokers over
the age of 18 years consulting their primery care physi-
cian will be recruited.
Study subjects
Study population
All the adult smoker population over the age of 18 con-
sulting their primary care physician for any reason and
who do not fulfil the exclusion criteria.
Exclusion criteria
Previous diagnosis of COPD by spirometry. Patients
with counterindication to spirometry. Patients without a
telephone. Patients with communication difficulties: cog-
nitive and/or sensorial deterioration, language.
Patients with severe disease of poor prognosis (life
expectancy less than one year). Patients with another
respiratory disease: asthma, neoplasm of the respiratory
tract, pulmonary thromboembolism, pulmonary tubercu-
losis, interstitial diseases. Patients who do not give writ-
ten informed consent to participate in the study.
Sample size and selection method
To carry out the main objective of the study, sample size
calculation will be performed according to the following
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to 10% between the two groups in regard to smoking cessa-
tion, a proportion of 5% of smoking cessation in one of the
groups accepting an alpha risk of 0.05 and a beta risk of
0.10 in a bilateral contrast, 187 smokers are required in the
control group and 187 smokers in the intervention group.
It is assumed that 5% of smokers will withdraw the study.
Study variables
The study data will be collected using a structured ques-
tionnaire and data collection sheets specifically designed
for this objective. The structured questionnaire will
include the following data: sociodemographics (age, sex,
etc.), clinical history, smoking habit, respiratory sympto-
matology, smoking dependence test and smoking cessa-
tion motivation test. The data collection sheets will
include information related to the spirometric results,
peak expiratory flow rate and the carbon monoxide test
when performed.
The following variables will be collected on forced
spirometry, reference values using the ATS reference
equations will be used:
- Forced vital capacity (FVC): a result ≥ 80% of the
reference value will be considered normal.
- Forced expiratory volume in the first second (FEV1):
ar e s u l t≥ 80% of the reference value will be considered
normal.
-F E V 1 / F V CI n d e x :ar e s u l t s≥ 70 of the absolute
values will be considered normal.
Spirometry defined by FEV1/FVC < 70% will be consid-
ered as forced spirometry with an obstructive pattern. A
restrictive pattern will be that with FEV1/FVC values ≥
70% and an FVC <80% and a mixed pattern will be defined
with spirometry values of FEV1/FVC <70% and FVC <80%.
- Forced expiratory flow between 25% and 75% or
mean expiratory flows (FEF 25-75%): normal results will
be considered as > 60% of the reference value.
- Bronchodilator test (BDT): will be considered posi-
tive when the FEV1 after the BDT increases a percen-
tage ≥ 12% and ≥ 200 ml in absolute values.
The following tests will also be carried out:
- Pulsioxymetry.
- Anthropometric variables: height and weight.
The following data will be collected using a question-
naire and will be compared with revision of the clinical
histories in each of the phases:
- Usual symptomatology: expectoration, cough, pre-
sence of wheezing, dyspnoea.
- Sociodemographic variables: age, gender, occupation,
level of education, municipality of residence and site of
home (rural, semi-urban, urban).
- Exposure to tobacco (measurement in packs / year),
years smoking, age at initiation of smoking, current
smoking intake (measurement in cigarettes / day).
- History of disease and active medication.
Procedures
During the selection visit the primary care physician will
inform the candidates for participation as to the nature
of the study and will offer them the possibility to parti-
cipate in the study. If the patient agrees, informed con-
sent will be requested, and a series of tests will be
indicated (spirometry, peak expiratory flow rate, smok-
ing dependence test, smoking cessation motivation test
and a structured questionnaire on sociodemographics
data, history of disease, smoking habit, respiratory symp-
tomatology, etc).
On visit 0, the primary care physician will give a brief
structured smoking cessation advice to all patients com-
bined with a detailed and structured discussion of the
spirometric results.
After this visit the patients will be randomised in two
arms (control and intervention groups). Randomisation
will be performed using a computer programme. Ran-
domisation will be carried out by the Coordinating
Centre.
Both groups will be followed up by telephone at three
(visit 1) and six months (visit 2) and at one-year (visit 3)
and two-year(visit 4). During the follow up visits brief
structured smoking cessation advice will be reinforced
in the control group but the spirometric results will not
be discussed. In the intervention group brief structured
smoking cessation advice will be reinforced with a
detailed structured reminder discussion of the results
obtained from the spyrometry of visit 0. Follow up visits
1a n d2w i l lb eu n d e r t a k e nb yt e l e p h o n ea n dt h e
patients will be asked about their smoking habit and
will be given a brief questionnaire.
O n em o n t hb e f o r ev i s i t s3a n d4b o t hg r o u p sw i l l
undergo the same series of tests performed prior to visit
0 with the exception of the peak expiratory flow rate.
Spirometry will be done only in the intervention group.
On visits 3 and 4, the same intervention will be done.
On both visits 3 and 4 all the participants who report
smoking withdrawal will undergo the carbon monoxide
test.
Analysis plan
To achieve the first objective the rates of withdrawd and
reduction of the smoking habit of the two groups will
be compared at 6, 12, and 24 months.
To achieve the second objective the sensitivity, specifi-
city and positive and negative predictive values of peak
flow compared to spirometry will be determined.
For the third objective, the proportion of COPD and
the severity of air flow limitation will be determined
according to different study variables (age, sex, smoking
habit, symptoms...).
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The participants will be informed of the objectives of
the study and the activities related to their participation
in the study: number of visits, complementary tests,
information of the results. The informed consent will
describe the ethical conditions and the participant’s
right to intimacy, anonymity, confidentiality, withdrawal
and information. Patients in whom a previously undiag-
nosed disease is detected will be provided with the usual
diagnostic and therapeutic methods available through
their reference physician who will be responsible for
integrating the information and providing the best ther-
apeutic and diagnostic options to the patient.
The data will be included in a database for data man-
agement with programmes of statistical analyses in
which no reference will be made as to the identity of
the subjects. Data confidentiality and anonymity will be
ensured according to Law 15/1999 on data confidential-
ity during both the execution of the project and in the
presentations and publications derived therewith. The
investigators are committed to respecting the norms of
good clinical practice, as well as the requirements of the
Helsinki Declaration.
Authorisation will be requested from the directors of
all the primary care centres and participating depart-
ments to access the clinical histories. The rules of the
Catalan Health Institute with respect to access to clini-
cal information for investigation will be fully respected.
This study has been approved by the Ethical Commit-
tee of Clinical Investigation of the Primary Care
Research Institute Jordi Gol (Barcelona, Spain) on May
26
th 2010.
Discussion
The results of this study will provide better knowledge
on how the results obtained with spirometry influence
smokers in relation to the rate of withdrawd and aspects
little known such as the use of the spirometry results to
reinforce repeated and reminder brief structured anti-
smoking advice.
The use of spirometry as a motivational tool to cease
smoking currently continues to be very controversial. In
2007, Wilt et al [31] published a systematic review of
the role of spirometry to increase the rates of smoking
cessation and concluded that the current evidence avail-
able is insufficient to determine the benefit obtained on
rates of smoking cessation with the use of spirometry
compared with other cessation methods.
Of all the studies reviewed only one clinical trial eval-
uated the benefits of the use of spirometry with negative
r e s u l t s .L a t e ri n2 0 0 8 ,P a r k e se ta l[ 3 0 ]p u b l i s h e da
study in which a benefit was found in the reduction of
smoking using the pulmonary age achieved in the spiro-
metry versus the real age as the intervention. The rate
of smoking abandonment achieved at 12 months was
13.6% in the intervention group versus 6.4% in the con-
trol group, with a difference of 7.2% with a confidence
interval of [2.2-12.1].
Previous observational studies such as that by Gorecka
et al [28] observed a benefit in the rate of smoking ces-
sation using the results obtained in spirometry, particu-
larly in patients with chronic airflow obstruction.
On the other hand, we expect the rate of participation
in the present study to be high, based on the experience
reported in previous studies, especially taking into aco-
cunt that it is the primary physician of the patient who
offers the possibility of participating and that participa-
tion does not imply invasive tests or pharmacological
interventions.
With regard to the validity and reliability of the data
collected, the difficulty and variability of some of the
tests requested in the study for both the health care per-
sonnel as well as the patient (i.e. performing spirometry)
are of note. Thus, consensus meetings among the pro-
fessionals performing the study tests will be held with
the aim of homogenising criteria and their practice. The
SEPAR recommendations for performing forced spiro-
metry will be followed. Likewise, meetings with the pri-
mary care physicians are foreseen to standardise the
methodology of the interventions proposed in both
groups of patients. In regard to the brief structured
advice, the intervention recommended by the Smoking
Group of the Spanish Society of Family and Community
Medicine will be used.
Lastly, to reduce variability due to the measurement
tools, it has been proposed that all the spirometers, peak
flows and carbon monoxide tests used in the study be
the same model and trademark.
In conclusion, we believe that the results of this study
will provide better knowledge of the usefulness of spir-
omery in the increase in the currently controversial rate
of smoking cessation and the utility of repeated use of
brief structured advice in increasing and maintaining
these rates over time.
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